Health
Cancer Prevention
Pharmaceutical

Agenus

$2.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-3.38%) Today
+$0.04 (1.22%) After Hours

Why Robinhood?

You can buy or sell Agenus and other stocks, options, ETFs, and crypto commission-free!

About

Agenus Inc. Common Stock, also called Agenus, is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Read More Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Employees
294
Headquarters
Lexington, Massachusetts
Founded
1994
Market Cap
397.25M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.49M
High Today
$2.97
Low Today
$2.85
Open Price
$2.97
Volume
425.44K
52 Week High
$3.88
52 Week Low
$1.54

Collections

Health
Cancer Prevention
Pharmaceutical
Medical
Biotechnology
Technology
US
North America

News

Yahoo FinanceMay 10

Agenus Q1 Earnings Beat Estimates, Revenues Miss

Agenus Inc. AGEN reported first-quarter 2019 earnings of 12 cents per share against the Zacks Consensus Estimate of a loss of 30 cents and the year-ago quarter’s loss of 42 cents. The company generated revenues of $8.6 million, which includes non-cash royalties, compared with no revenues in the year-ago quarter. Revenues marginally missed the Zacks Consensus Estimate of $9 million. Shares of the company have rallied 21% year to date compared with the industry’s growth of 3.3%. Quarterly Highlights Resea...

226
Yahoo FinanceMay 9

Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update

13
Yahoo FinanceMay 9

Agenus (AGEN) Surpasses Q1 Earnings Estimates

Agenus (AGEN) delivered earnings and revenue surprises of 140.00% and -4.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

105

Earnings

-$0.40
-$0.23
-$0.05
$0.12
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.